Advertisement

Lifetime perspectives on dementia prevention: The role of ‘preventive’ polypharmacy

      Within the new reality of multimorbidity, co-occurrence of chronic diseases necessitates frequent and simultaneous use of multiple medications. These combinations of medications easily lead to the simultaneous use of 5 or more drugs (‘polypharmacy’). Contrary to widespread belief, it has been shown that preventive cardiovascular medications form the backbone of polypharmacy among adults, present in up to 90 % of all occurrences of polypharmacy on a population-level [
      • Licher S.
      • et al.
      Epidemiology of polypharmacy in the general population: 27-year prospective cohort study.
      ]. Is this a sign of preventive health or are these preventive drugs part of inappropriate polypharmacy that could potentially harm cognitive health?

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Licher S.
        • et al.
        Epidemiology of polypharmacy in the general population: 27-year prospective cohort study.
        J. Am. Med. Dir. Assoc. 2020; 21: 1177-1179
        • Mangin D.
        • et al.
        International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): position statement and 10 recommendations for action.
        Drugs Aging. 2018; 35: 575-587
        • SPRINT MIND Investigators for the SPRINT Research Group
        Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial.
        JAMA. 2019; 321: 553-561
        • Mortensen M.B.
        • Nordestgaard B.G.
        Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort.
        Lancet. 2020; 396: 1644-1652
        • van der Ploeg M.A.
        • et al.
        Recommendations for (discontinuation of) statin treatment in older adults: review of guidelines.
        J. Am. Geriatr. Soc. 2020; 68: 417-425